Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 92%
filed 2026-10-21
Item 1.01
Quanome Technologies entered into an At The Market (ATM) Offering Agreement with Maxim Group LLC on October 21, 2026, authorizing the sale of up to $9.75 million in common stock. ATM offerings are unregistered equity issuances that dilute existing shareholders and are a classic signal of capital-raising activity at small- and mid-cap issuers. The filing explicitly discloses the offering price cap, the 3.0% transaction fee structure, and intended use of proceeds for working capital and potential acquisitions, all hallmarks of a dilutive equity issuance under Item 1.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-10-21
Item 3.02
The Company issued 9,962,645 shares of common stock to Evervolt on October 15, 2026, as payment of the third tranche ($30.0 million) of the IP Purchase Price under an intellectual property purchase agreement. The shares were issued without registration under the Securities Act in reliance on Section 4(a)(2), and the issuance is currently deferred due to an Ownership Limitation (4.99% beneficial ownership cap). This is a classic dilutive equity issuance to satisfy a material financial obligation, fitting the definition of a private placement under Item 3.02.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-10-21
EX-99.1
Ascentage Pharma announced that lisaftoclax (APG-2575) has been granted Breakthrough Therapy Designation (BTD) by China's NMPA for treatment-naïve CLL/SLL in combination with acalabrutinib, a significant regulatory milestone that accelerates development and enables priority review and potential conditional approval pathways.
View raw filing on EDGAR →
6-K
Auditor Change
confidence 95%
filed 2026-10-21
The 6-K discloses the dismissal of TAAD LLP as the Company's independent registered public accounting firm effective October 16, 2026, and the appointment of Mercurius & Associates LLP as successor auditor. The timing is material: TAAD had not completed its audit of the fiscal year ended December 31, 2025, and will not issue a report on those financial statements. This mid-audit dismissal and replacement is a significant auditor change that would affect a reasonable investor's assessment of audit independence and financial reporting reliability.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 75%
filed 2026-10-21
EX-99.1
The press release discloses termination of an additional purchase right in a registered direct offering announced October 14, 2026. While the termination itself removes future dilution risk, the underlying event is a registered direct offering of ordinary shares and pre-funded warrants with an $18 million additional purchase option. The core transaction—a direct offering of equity securities—is a dilutive issuance material to investors assessing capital structure and shareholder dilution.
View raw filing on EDGAR →
6-K
Auditor Change
confidence 95%
filed 2026-10-21
EX-99.1
The exhibit discloses the dismissal of Price Waterhouse & Co. S.R.L. as the Company's independent registered public accounting firm, effective October 21, 2026, following shareholder approval of voluntary winding up. This is a direct auditor change under Item 304(a)(1) of Regulation S-K. The disclosure includes the auditor's agreement letter and details of any disagreements or reportable events, including a prior material weakness in internal controls over business combination accounting and substantial doubt about going concern in the prior year audit report.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-10-21
The filing discloses entry into a Securities Purchase Agreement on September 25, 2026, for the sale of 9,444 shares of Series A Convertible Preferred Stock at $100 per share ($944,400 aggregate), with conversion rights into common stock at $10 per share. This is an unregistered private placement under Section 4(a)(2) and Regulation D Rule 506(b), representing a dilutive equity issuance to raise capital for operational purposes and refinery development. The concurrent Creto investment of 6,000 shares ($600,000) reinforces the capital-raising nature of the transaction.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 95%
filed 2026-10-21
The 6-K body contains a Notice to Shareholders announcing interim dividends declared at the Annual and Extraordinary Shareholders' Meeting held on October 21, 2026, in the amount of R$ 30,000,000.00 (R$ 0.30115808232 per common share), payable as of November 16, 2026. This is a material dividend distribution to shareholders that would affect investor assessment of capital allocation and shareholder returns.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-10-21
Item 1.01
Drugs Made In America Acquisition Corp. entered into Amendment No. 1 to its Amended and Restated Definitive Merger Agreement with Power Analytics Global Corp., dated October 13, 2026, materially modifying the merger consideration structure. The amendment introduces a Standalone Closing Valuation of US$1.71 billion (down from US$2.85 billion) contingent on whether PAGC completes its acquisition of APQC Inc. and UltraSolar intellectual property by November 1, 2026.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-10-21
Item 8.01
The Company's board engaged Joel A. Gallo as an independent evaluator to render a fairness opinion on PAGC's standalone valuation of $1.71 billion by October 26, 2026, after the original fairness opinion firm terminated its engagement due to inability to provide the dual opinion structure required for intellectual property valuation. This change in fairness opinion engagement is a material procedural development affecting a key closing condition of the merger.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-21
Item 1.01
Reborn Coffee entered into a Master Product Supply Agreement with Visvita Corporation on October 11, 2026, establishing a framework for supplying aloe vera and other beverages with a $30 million first-year volume target and an initial $2 million purchase order already secured. This material commercial contract represents a significant operational and revenue milestone for the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-10-21
Item 7.01
The filing discloses the appointment of David Thomas as Senior Vice President of Project Development of Ambler Metals LLC, a 50/50 joint venture operating company. While the press release also announces completion of the 2026 field program, the principal executive action disclosed is the appointment of a senior officer to lead engineering and project development for the Arctic Project. The appointment is material given Thomas's extensive experience and his role in advancing the project toward a construction decision targeted for 2028.
View raw filing on EDGAR →
6-K
Financial Other
confidence 75%
filed 2026-10-21
EX-99.1
This press release discloses two material financial impacts expected in Q4 2026: (1) a CAD $96 million net income contribution from KeyCorp ownership (adjusted to CAD $104 million excluding intangible amortization), and (2) a CAD $55 million deferred tax asset write-down resulting from Chile's corporate income tax rate reduction. While the release previews earnings impacts ahead of the December 2 earnings release, it is not itself an earnings release but rather a discrete announcement of specific accounting and valuation adjustments. The tax write-down is a material impairment-like charge, but the disclosure bundles it with equity-method earnings guidance, making the overall event a financial adjustment announcement rather than a pure impairment or earnings release.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-10-21
This 6-K discloses the completion and consummation of a merger of shares whereby SABESP acquires all shares of EMAE (Empresa Metropolitana de Águas e Energia S.A.) in a stock-for-stock transaction at an exchange ratio of 1.31950000000 SABESP shares per EMAE share. The filing confirms the end of the withdrawal right period (October 19, 2026) with no dissenting shareholders, and sets October 27, 2026 as the date EMAE shareholders will receive SABESP shares and EMAE's shares will cease trading on B3. This is a material acquisition/change of control transaction that materially affects the registrant's capital structure and operations.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-21
The filing discloses third-quarter 2026 operational metrics for COPEL's distribution business, specifically that the billed grid market grew 5.8% in 3Q26 and 5.0% year-to-date, driven by residential and commercial segment performance, higher temperatures, and reduced solar generation offsetting distributed generation. While this is operational performance data rather than a formal earnings release or periodic financial report, it constitutes a material disclosure of quarterly business performance that would affect a reasonable investor's assessment of the company's operational trajectory and market conditions.
View raw filing on EDGAR →
6-K
Bankruptcy Filing
confidence 95%
filed 2026-10-21
The 6-K discloses an involuntary Chapter 11 bankruptcy petition filed on October 21, 2026 against Braskem America Finance Company, an indirect subsidiary of Braskem S.A., by creditors holding approximately 47% of the 7.125% Notes due 2041 (approximately US$272 million of US$589 million outstanding). This is a terminal event materially threatening the registrant's financial stability and capital structure, even though the parent company and operating subsidiaries are not listed as debtors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-10-21
Item 2.02
Las Vegas Sands issued a press release on October 21, 2026 announcing third quarter 2026 financial results, including net revenue of $3.22 billion, net income of $352 million, and diluted EPS of $0.48. The Item 2.02 disclosure explicitly states the press release is attached as Exhibit 99.1 and incorporated by reference, which is the standard format for earnings releases under Item 2.02 of Form 8-K.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-10-21
Item 2.02
NVE Corporation disclosed quarterly and six-month financial results for the period ended September 30, 2026, via press release, including revenue, net income, earnings per share, balance sheet data, and management commentary from CEO Peter G. Eames.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-10-21
Item 8.01
NVE Corporation's Board approved a quarterly cash dividend of $1.00 per share payable November 30, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-10-21
Item 2.02
ARMOUR Residential REIT, Inc. disclosed Q3 2026 unaudited financial results, including a GAAP net loss of $(327.0) million, book value per share of $14.55, net interest income of $83.7 million, and distributable earnings of $102.3 million, along with detailed financial statements and management commentary on market conditions.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 95%
filed 2026-10-21
EX-99.1
The exhibit discloses material changes to the remuneration package for Dr David Stamler, the Company's Chief Executive Officer and Managing Director, effective 15 October 2026. The announcement details revised base salary (US$525,000), STI arrangements, severance terms, and change-of-control provisions, with the Board noting it has approved these changes and intends to seek shareholder approval for termination benefits at the upcoming annual general meeting. This is a classic executive compensation disclosure under the governance domain.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-10-21
Item 8.01
Genprex disclosed peer-reviewed research published in Mechanisms of Ageing and Development demonstrating that TUSC2—the therapeutic gene underlying its lead oncology program REQORSA®—plays a foundational role in brain health and mitochondrial function. While the study was conducted in mice and does not evaluate REQORSA as a treatment for neurodegeneration, the findings expand scientific understanding of TUSC2's biological significance beyond cancer and identify potential new therapeutic avenues in age-related cognitive disorders. This is a material operational/strategic disclosure of research supporting the scientific rationale for the company's core asset, though it does not fit neatly into a specific category (not a product approval, partnership, or regulatory milestone, but a research validation event).
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-10-21
Item 2.02
Parke Bancorp issued a press release on October 21, 2026 reporting third quarter and nine-month 2026 earnings results, including net income of $12.2 million for Q3 2026 (up 14.5% YoY) and $36.2 million for nine months (up 35.9% YoY), along with detailed financial metrics such as revenue, assets, net interest margin, and per-share earnings. This is a standard quarterly earnings disclosure furnished as Exhibit 99.1 under Item 2.02, which is material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-10-21
Item 2.02
Plumas Bancorp disclosed its financial results for the three months ended September 30, 2026, via a press release furnished as Exhibit 99.1. The filing reports record third-quarter 2026 earnings of $11.4 million ($1.64 per share), a significant increase from $5.1 million ($0.74 per share) in Q3 2025, along with detailed financial metrics including net interest income, provision for credit losses, and return on assets/equity. This is a standard quarterly earnings release disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Financial Other
confidence 50%
filed 2026-10-21
Item 1.01
Banzai International entered into a Repurchase Agreement involving a $1.5 million warrant buyback related to an existing senior secured convertible note and warrant issuance from June 2025. The agreement also addresses investor participation rights in an upcoming offering and modifies security holder rights.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-10-21
Item 2.02
This is a clear earnings release for the first fiscal quarter ended September 30, 2026. The press release reports net income of $3.0 million (up 15.3% year-over-year), earnings per share of $0.96, net interest income of $10.8 million, and key balance sheet metrics including loan and deposit growth. The disclosure is filed under Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for quarterly earnings disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-10-21
Item 2.02
Fidelity D & D Bancorp issued a press release on October 21, 2026 disclosing its unaudited consolidated financial results for the three and nine-month periods ended September 30, 2026. The release reports net income of $8.9 million ($1.53 per diluted share) for Q3 2026 and $24.2 million ($4.16 per diluted share) year-to-date, with detailed operating results, balance sheet metrics, and asset quality information. This is a standard quarterly earnings disclosure furnished under Item 2.02.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-10-21
Item 1.01
Professional Diversity Network entered into Securities Purchase Agreements to issue 146,713 shares of common stock at $1.704 per share (60% of the prior closing price) for approximately $250,000 in gross proceeds. The unregistered sale relied on Section 4(a)(2) and Regulation D exemptions to accredited investors, representing a dilutive private placement to raise capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-10-21
Item 3.02
The filing discloses an unregistered sale of 106,974.359 shares of common stock at $9.75 per share for an aggregate offering price of $1,043,000, conducted pursuant to subscription agreements and exempt under Section 4(a)(2) and Regulation D. This is a classic private placement of equity securities that dilutes existing shareholders and raises capital for the company.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-10-21
Item 2.02
Cathay General Bancorp announced its financial results for the third quarter ended September 30, 2026, reporting net income of $95.2 million and diluted EPS of $1.43, along with record net interest income, loan and deposit growth, and improved asset quality metrics.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-10-21
Item 2.02
FS Bancorp issued its Q3 2026 earnings release on October 21, 2026, disclosing net income of $4.9 million or $0.63 per diluted share, along with detailed financial results, segment performance, and asset composition.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-10-21
Item 8.01
The Board declared a regular quarterly cash dividend of $0.29 per share, payable November 20, 2026, marking the 55th consecutive quarterly cash dividend and demonstrating consistent shareholder returns and capital management policy.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-10-21
Item 8.01
The Company increased the maximum aggregate offering price under an at-the-market (ATM) sales agreement with Benchmark and StoneX by $950,000 to a total of $6,421,000. This is a dilutive equity issuance under an ATM offering facility, which is a material capital-raising event that increases share dilution and is commonly disclosed under Item 8.01 for ATM program amendments.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-10-21
Item 5.03
Capstone Holding Corp. implemented a 1-for-30 reverse stock split effective October 19, 2026, which was previously approved by stockholders at the June 18, 2026 annual meeting. The reverse split affects share count, trading mechanics, and equity award adjustments, and is material to investors despite being a routine capital structure action.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-10-21
Item 2.03
H.B. Fuller Company completed the issuance and sale of $850 million in aggregate principal amount of 7.625% Notes due 2034. The notes represent a material new direct financial obligation that significantly affects the company's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-10-21
Item 2.02
Live Oak Bancshares announced third quarter 2026 financial results on October 21, 2026, disclosing net income of $24.3 million ($0.52 per diluted share), with detailed quarterly income statements, balance sheets, and comparative metrics. The press release attached as Exhibit 99.1 is a standard earnings announcement containing comprehensive financial results and management commentary, clearly constituting an earnings release under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-10-21
Item 2.02
Knight-Swift Transportation Holdings Inc. issued a press release on October 21, 2026 announcing its financial results for the quarter ended September 30, 2026. The disclosure includes detailed quarterly financial metrics (revenue of $2.2 billion, net income of $118.3 million, diluted EPS of $0.72), segment performance data, and management commentary on market conditions and outlook. This is a standard quarterly earnings release filed under Item 2.02 (Results of Operations and Financial Condition), which is material to investors assessing the company's financial performance and operational trends.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-10-21
The filing discloses entry into a definitive Agreement and Plan of Merger on October 20, 2026, between APEX Tech Acquisition Inc. and Korai Flix Inc., with a $3.5 billion valuation. Item 1.01 explicitly covers "Entry into a Material Definitive Agreement," and the merger contemplates a complete change of control, re-domiciliation, and name change to "Krflix Group Inc." This is a material acquisition transaction requiring shareholder approval and SEC registration.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-21
The filing discloses a $249 million U.S. Government grant for the Port MacKenzie Rail Extension, which will provide critical transportation infrastructure directly supporting Nova Minerals' planned antimony processing and refining hub in Alaska. This is a material operational and strategic development—a major infrastructure milestone enabling the company's critical minerals project—but does not fit neatly into specific event categories (not M&A, not a contract, not a regulatory approval per se). The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) via press release, indicating it is material information about the company's operational prospects and project development.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-10-21
The filing discloses that Vivos received a deficiency notice from Nasdaq in April 2026 for failing to meet continued listing requirements (minimum $2.5M stockholders' equity, $35M market value, or $500K net income). On October 20, 2026, Nasdaq confirmed compliance with the stockholders' equity requirement following the SOD acquisition, but explicitly warned that "if the Company fails to evidence compliance upon the filing of its next periodic report, the Company may be subject to delisting." This is a material delisting risk disclosure under Item 8.01, as the company remains conditionally compliant and faces imminent delisting if it fails to maintain the equity threshold.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-10-21
Soluna announced entry into a definitive agreement to form a jointly owned company with Applied Digital Corporation to develop a 50 MW critical IT data center. Under the Transaction Agreement, Soluna will contribute land and power-related project assets to the Project Company in exchange for a 49% ownership stake, while Applied will provide capital for a 51% stake. This constitutes a material acquisition/formation of a joint venture involving significant asset contribution and equity restructuring, disclosed under Item 7.01 (Regulation FD Disclosure) with a press release exhibit.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-21
EX-99.1
The press release announces a non-binding Memorandum of Understanding between Green Circle Decarbonize Technology, SANVO Fine Chemicals, and Menzies Eurus Aviation to develop and deploy energy-saving solutions across airport facilities. This is a strategic partnership announcement involving the integration of the Company's decarbonization technology with partners' operational networks and chemical formulations. While the MOU is explicitly non-binding, the disclosure of a material strategic partnership with named third parties that could affect the Company's business development, market reach, and revenue prospects qualifies as a material operational event. The prior September 2026 Partnership Agreement with SANVO (appointing them as sole supplier and exclusive manufacturer) reinforces the materiality of this partnership ecosystem.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-10-21
The filing discloses an amendment to the engagement letter for Tom DaPolito, the Interim Chief Financial Officer, effective October 16, 2026. The Amendment modifies compensatory arrangements by: (i) extending the engagement term through October 16, 2027; (ii) providing full immediate vesting of all outstanding and unvested stock options upon a change of control; and (iii) extending the post-termination exercise period for vested options to three years. These modifications to equity vesting and exercise rights constitute material changes to executive compensation arrangements under Item 5.02(e).
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-10-21
The filing discloses Imunon's entry into an Asset Purchase Agreement with VoxelDox Therapeutics to sell its ThermoDox® assets, including trademarks, regulatory filings, and manufacturing know-how. The transaction involves contingent consideration including equity (4.76% of VoxelDox), up to $16.5 million in milestone payments, and royalties on future sales. This is a material disposition of assets that would affect investor assessment of the company's portfolio and capital allocation strategy.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-21
NextTrip announced a joint venture agreement with The Travel Agent Next Door Inc., a Canadian travel agency network with 1,850 agents and C$620 million in annual travel sales. The venture is designed to connect Canadian viewers of JOURNY TV with travel planning and booking through an established partner network, creating a new revenue channel for travel commissions in Canada. This is a material strategic partnership and operational initiative that expands the company's business into a new geographic market through an established operator, but does not constitute a traditional M&A transaction, acquisition, or material contract requiring Item 1.01 disclosure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-10-21
The filing discloses Tron Inc.'s Super Representative (SR) node achieving No. 1 ranking on the TRON network with 3.71 billion delegated TRX tokens, and the company's intention to operate multiple nodes to expand on-chain revenues and deepen infrastructure integration. This is a strategic operational milestone in the company's cryptocurrency and blockchain infrastructure business, distinct from earnings, M&A, or other named event types. While material to investors assessing the company's competitive position and revenue expansion strategy, it is primarily an operational/strategic business update rather than a financial event, governance change, or existential matter.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-10-21
EX-99.1
The exhibit discloses a previously announced private placement of 862,069 ordinary shares at $0.58 per share for $500,000 under a Securities Purchase Agreement dated June 16, 2026. Although the transaction has not yet closed as of October 21, 2026 due to non-receipt of full payment, the Company's update regarding the pending issuance and the termination threat constitute a material disclosure of dilutive equity issuance activity. This falls squarely within the dilutive_issuance category as an unregistered private placement of equity securities.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-10-21
EX-99.1
Genenta Science received a Nasdaq notification on October 16, 2026, that it failed to maintain the minimum bid price of $1.00 per share for 30 consecutive business days. The company has been given 180 calendar days (until April 14, 2027) to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, as it directly threatens the company's continued listing on Nasdaq Capital Market.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-10-21
The filing discloses the appointment of Amy Shi as Executive Chair of the Board effective October 15, 2026. While the disclosure also includes compensatory arrangements (annual cash of $120,000 escalating to $240,000, equity award of $250,000 reference value, and severance provisions), the principal disclosed action is the appointment of Shi to an executive leadership role. The appointment of an Executive Chair is a material governance event affecting the registrant's leadership structure.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-10-21
EX-99.1
This exhibit is a press release announcing STAK Inc.'s financial results for fiscal year 2026 (ended June 30, 2026). It discloses revenues of $28.2 million (up 13.21% YoY), a return to net income of $0.4 million (versus a net loss of $5.7 million in FY2025), and includes consolidated balance sheets, statements of operations, and cash flow statements. The document explicitly states "STAK Inc. Announces Financial Results for Fiscal Year 2026" and contains the full audited financial statements, making it a classic earnings release. This is material to investors as it shows the company's return to profitability and significant operational changes in product portfolio.
View raw filing on EDGAR →